The document provides an overview of microbial monitoring in a manufacturing area. It discusses:
1) The purpose of an environmental monitoring program is to provide crucial information on the quality of the aseptic processing environment during manufacturing and to prevent the release of contaminated batches.
2) Microbial monitoring tests for viable and non-viable particles in critical areas like cleanrooms, tank rooms, and packaging areas to demonstrate control of microorganisms.
3) Sources of contamination can come from air, personnel, equipment, cleaning agents and more. Monitoring must meet regulatory standards from agencies like FDA, ISO, and USP.
Microbiological Environmental Monitoring in Pharmaceutical Facilitydelli_intralab
Merupakan jurnal tentang microbiological environment monitoring in pharma facility
Untuk informasi lebih lanjut atau diskusi mengenai environment monitoring, silahkan hubungi delli.intralab@gmail.com
The document discusses environmental monitoring programs in clean rooms and aseptic processing areas. It describes the purpose of monitoring to control microbial and particle contamination and prevent release of contaminated products. Key aspects covered include viable and non-viable monitoring of air, surfaces, personnel and drains using methods like air sampling, surface swabbing and particle counting. It provides classification standards and action limits for contamination and validation procedures for HVAC systems. Personnel are identified as the main challenge to control in aseptic processing.
Considering: Environmental monitoring guidance, Background to USP <1116>, Main changes and debates Method limitations, Incident rates, Frequencies of monitoring, Locations of monitoring, Other changes, Regulatory issues and Rapid methods
Routine environmental monitoring ensures a safe compounding environment and is used to test for viable and nonviable particle levels. Environmental monitoring includes testing the temperature, pressure differential, nonviable particles, surface sampling, and viable electronic device sampling at least every six months. It also involves monitoring humidity, sound, and lighting levels. Environmental sampling should occur throughout the entire compounding area including the ISO Class 5 PEC, buffer areas, ante-areas, and segregated compounding areas.
This document summarizes the sampling locations and methods used for microbiological environmental monitoring at a pharmaceutical facility. Samples were taken from different areas classified based on their cleanliness requirements, including water systems, laboratories, manufacturing areas, and packaging rooms. The objectives, methods, and specific sampling locations are described to review microbiological quality control testing. Surface and air samples are analyzed to ensure limits for viable particles are met to maintain appropriate cleanliness levels in the facility.
دورة مختصرة عن المعمل الميكروبيولوجى ودوره فى شركات ومصانع الادوية
المحتوى :
- Introduction to Microbiology
- Microbiology lab. Overview
- Microbiology Lab. Role
- Pharmaceutical Microbiology
- Microbiological tests for pharmaceuticals
الميكروبيولوجى ببساطة
To maintain the desired SAL at the plant is task which demands great care and control over Man, Machine & Method. This summarize work will definitely help you as hand note.
The document provides an overview of microbial monitoring in a manufacturing area. It discusses:
1) The purpose of an environmental monitoring program is to provide crucial information on the quality of the aseptic processing environment during manufacturing and to prevent the release of contaminated batches.
2) Microbial monitoring tests for viable and non-viable particles in critical areas like cleanrooms, tank rooms, and packaging areas to demonstrate control of microorganisms.
3) Sources of contamination can come from air, personnel, equipment, cleaning agents and more. Monitoring must meet regulatory standards from agencies like FDA, ISO, and USP.
Microbiological Environmental Monitoring in Pharmaceutical Facilitydelli_intralab
Merupakan jurnal tentang microbiological environment monitoring in pharma facility
Untuk informasi lebih lanjut atau diskusi mengenai environment monitoring, silahkan hubungi delli.intralab@gmail.com
The document discusses environmental monitoring programs in clean rooms and aseptic processing areas. It describes the purpose of monitoring to control microbial and particle contamination and prevent release of contaminated products. Key aspects covered include viable and non-viable monitoring of air, surfaces, personnel and drains using methods like air sampling, surface swabbing and particle counting. It provides classification standards and action limits for contamination and validation procedures for HVAC systems. Personnel are identified as the main challenge to control in aseptic processing.
Considering: Environmental monitoring guidance, Background to USP <1116>, Main changes and debates Method limitations, Incident rates, Frequencies of monitoring, Locations of monitoring, Other changes, Regulatory issues and Rapid methods
Routine environmental monitoring ensures a safe compounding environment and is used to test for viable and nonviable particle levels. Environmental monitoring includes testing the temperature, pressure differential, nonviable particles, surface sampling, and viable electronic device sampling at least every six months. It also involves monitoring humidity, sound, and lighting levels. Environmental sampling should occur throughout the entire compounding area including the ISO Class 5 PEC, buffer areas, ante-areas, and segregated compounding areas.
This document summarizes the sampling locations and methods used for microbiological environmental monitoring at a pharmaceutical facility. Samples were taken from different areas classified based on their cleanliness requirements, including water systems, laboratories, manufacturing areas, and packaging rooms. The objectives, methods, and specific sampling locations are described to review microbiological quality control testing. Surface and air samples are analyzed to ensure limits for viable particles are met to maintain appropriate cleanliness levels in the facility.
دورة مختصرة عن المعمل الميكروبيولوجى ودوره فى شركات ومصانع الادوية
المحتوى :
- Introduction to Microbiology
- Microbiology lab. Overview
- Microbiology Lab. Role
- Pharmaceutical Microbiology
- Microbiological tests for pharmaceuticals
الميكروبيولوجى ببساطة
To maintain the desired SAL at the plant is task which demands great care and control over Man, Machine & Method. This summarize work will definitely help you as hand note.
The document summarizes the harmonized microbial limit tests established in 2006 by the USP, EP, and JP pharmacopeias. The tests include microbial enumeration tests to determine total aerobic microbial count and total yeast and mold count, as well as tests for specified microorganisms like E. coli, Salmonella species, and Candida albicans. The tests involve preparing samples, incubating them in various growth media, and observing colonies to quantify microbes and identify pathogens based on standardized methods, limits, and interpretations. The harmonization aligned the structure, methods, and acceptance criteria used across different pharmacopeias to ensure microbial safety of non-sterile pharmaceutical products.
Control on Cleanroom Environmental Monitoring (Pharmaceutical)Srinath Sasidharan
A general consideration of Environmental Monitoring in Pharmaceutical manufacturing area. Cleanroom Monitoring Tools and Utilities: Author Sreenath Sasidharan (Geltec Healthcare FZE)
This document provides standard operating procedures for cleaning equipment, facilities, and cleaning-in-place (CIP) at a pharmaceutical company. It outlines two types of equipment cleaning - Type A which requires dismantling equipment parts for cleaning, and Type B which is surface cleaning without dismantling. Critical areas for cleaning facilities are also identified. CIP is described as a method for cleaning pipes and vessels internally without disassembly using circulation of cleaning solutions. A typical CIP cycle involves pre-rinse, caustic wash, intermediate rinse, acid wash, and final rinse steps. Factors like temperature, concentration, contact time and pressure/turbulence are noted to impact cleaning effectiveness.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
This document appears to be a presentation on pharmaceutical environment monitoring and microbiology. It includes a speaker profile for an expert in microbiology, information on monitoring microbes in pharmaceutical environments using Rodac plates, and acknowledges an audience at the end of the presentation. The main topics covered are pharmaceutical environment monitoring, microbiology techniques like using Rodac plates, and microbes in pharmaceutical production settings.
This document discusses environmental microbial monitoring (EMM) in cleanrooms and pharmaceutical facilities. It provides an overview of EMM purposes and regulations, who performs EMM, what areas are monitored, sampling plans and methods used. Key points covered include:
- EMM determines microbial and particulate levels to ensure cleanroom quality and identify contamination sources.
- Quality Control and Assurance departments perform EMM to demonstrate safety and ensure GMP compliance.
- Non-viable air, viable air and surface samples are monitored from areas like personnel, equipment and facilities.
- Sampling frequency, sites and methods like air samplers, settle plates, contact plates and swabbing are discussed in accordance with regulations like USP 39
This document summarizes a dissertation report submitted by Ashish Diwakar on microbial limit testing conducted at IPCA Laboratories Ltd. in Ratlam, Madhya Pradesh, India. It provides an introduction to IPCA and the principles and requirements of microbial limit testing. Methods for total bacterial count, total fungal count, and testing for pathogens like E. coli, Salmonella, P. aeruginosa, and S. aureus are described. Both direct inoculation and membrane filtration methods are covered. Requirements include various culture media, glassware, and equipment. Test procedures and observations are outlined.
The document discusses the validation of water supply systems for pharmaceutical use. It outlines the validation process, which includes design qualification to verify the system design, installation qualification to confirm proper installation, operation qualification to test system functionality under static conditions, and performance qualification to demonstrate consistent performance over time under normal operating conditions. Routine monitoring, maintenance, and change control procedures are also required to ensure continued system operation and water quality as specified.
Contamination control and sterile manufacturingGeorge Wild
Microorganisms like bacteria, viruses, and fungal spores pose a contamination risk in sterile manufacturing. Cleanrooms with strict particle and airflow controls are needed. Personnel procedures aim to minimize shedding of microbes. Sterilization methods like heat aim to achieve a sterility assurance level of 1 in 1 million by killing all microbes or reducing their number below acceptable levels. Key factors in sterilization include the bioburden level and resistance of the most durable microorganism strain present.
This document discusses cleaning validation, which provides documented evidence that approved cleaning procedures will produce equipment suitable for processing pharmaceutical products. It defines different levels of cleaning validation based on risk. Key aspects covered include cleaning techniques, establishing acceptance criteria, sampling methods, analytical methods, and documentation requirements. The goal of cleaning validation is to achieve an appropriate level of cleanliness to avoid contamination between product batches.
This document summarizes a presentation on pharmaceutical waters from the USP chapter 1231. It discusses various types of bulk and sterile waters used in pharmaceutical applications, including their sources, uses, and quality standards. Purified water and water for injection are produced in large volumes on-site for use in non-parenteral and parenteral preparations, respectively. Source water is treated and purified to meet chemical, microbial, and endotoxin limits defined in pharmacopeial monographs. Water systems must be validated to reliably produce water meeting all specified quality attributes.
The document summarizes validation of an HVAC system for a pharmaceutical facility. It discusses the importance of HVAC systems in cleanrooms and outlines some key validation parameters to test, including:
1. Airflow pattern, velocity, and changes per hour to ensure proper airflow.
2. Filter leak testing and particulate counting to check filter performance and air quality.
3. Pressure differential, temperature, humidity, and sound level testing to validate environmental controls.
Validation of the HVAC system is necessary to demonstrate that it can consistently supply air meeting quality standards to maintain aseptic manufacturing conditions.
This presentation includes detail about cleaning levels,equipments for cleaning validation , steps for cleaning method validation and analytical method validation used for cleaning.
Environmental monitoring must include surface sampling plans with sampling locations, frequency, testing times, collection methods, documentation, action levels, and responses to exceedances. Surface sampling evaluates cleaning and disinfection procedures and work practices by testing for viable microorganisms. It is an important part of maintaining a suitable microbial environment according to USP <797>, and should be performed periodically in ISO classified areas including PECs, buffer areas, and ante-areas using contact plates and swabs on flat and irregular surfaces to identify the number and types of microorganisms present.
The document provides an overview of clean rooms, including their purpose, key components, classification standards, and importance in the pharmaceutical industry. A clean room is a controlled environment designed and maintained to reduce contamination through strict control of particulate matter and other pollutants. Clean rooms are classified based on standards like ISO and use HEPA filters to purify air circulation. Proper clean room certification and validation is important for ensuring safety and quality in pharmaceutical manufacturing as required by cGMP guidelines.
Cleaning validation is an important process in the pharmaceutical industry to ensure product safety and purity. It involves documenting evidence that an approved cleaning procedure will adequately clean equipment used in pharmaceutical production. The cleaning validation process includes planning, execution, analytical testing, and reporting phases. A cross-functional team plans the validation program, which involves grouping products, equipment, cleaning agents, and methods. Sampling techniques like swab and rinse sampling are used in the execution phase. Acceptance criteria are established and analytical tests are performed on samples to verify cleaning levels. A validation report documents the results and conclusions to obtain approval. Revalidation may be required if any changes are made to the cleaning process.
This document outlines procedures for performing microbial limit tests on pharmaceutical products. The tests are designed to qualitatively or quantitatively estimate the number of viable aerobic microorganisms present or detect designated microbial species. Several methods are described, including membrane filtration, pour plate, spread plate, and multiple tube dilution. Specific procedures are provided for testing for total aerobic count, E. coli, and Salmonella. Controls and interpretation of results are also described to validate the testing methods.
The document discusses pharmaceutical water systems. It begins by defining various types of high purity water like purified water, sterile purified water, water for injection, and sterile water for injection. It then discusses how purified water and water for injection are produced, typically through processes like distillation, ion exchange, or reverse osmosis. The document also covers considerations for storing and distributing high purity water, such as using stainless steel materials, minimizing dead legs, and sanitizing distribution systems through heat, ozone, or chemicals. Finally, it presents different options for setting up hot and cold storage and distribution systems.
Good Manufacturing Practice (GMP) regulations ensure that pharmaceutical products are consistently produced and controlled according to quality standards. GMP has regulations for facilities, equipment, personnel, sanitation, testing of raw materials and finished products, manufacturing, packaging, quality control, records, and stability. Following GMP procedures guarantees high quality products for consumers by minimizing risks of contamination and ensuring correct labeling and potency. Key aspects of GMP include written procedures, process validation, environmental monitoring, and record keeping. Strict adherence to GMP is important for producing safe, effective medicines.
Good Manufacturing Practice is a set of regulations, codes, and guidelines for the manufacture of drug substances and drug products, medical devices, in vivo and in vitro diagnostic products, and foods.
The document summarizes the harmonized microbial limit tests established in 2006 by the USP, EP, and JP pharmacopeias. The tests include microbial enumeration tests to determine total aerobic microbial count and total yeast and mold count, as well as tests for specified microorganisms like E. coli, Salmonella species, and Candida albicans. The tests involve preparing samples, incubating them in various growth media, and observing colonies to quantify microbes and identify pathogens based on standardized methods, limits, and interpretations. The harmonization aligned the structure, methods, and acceptance criteria used across different pharmacopeias to ensure microbial safety of non-sterile pharmaceutical products.
Control on Cleanroom Environmental Monitoring (Pharmaceutical)Srinath Sasidharan
A general consideration of Environmental Monitoring in Pharmaceutical manufacturing area. Cleanroom Monitoring Tools and Utilities: Author Sreenath Sasidharan (Geltec Healthcare FZE)
This document provides standard operating procedures for cleaning equipment, facilities, and cleaning-in-place (CIP) at a pharmaceutical company. It outlines two types of equipment cleaning - Type A which requires dismantling equipment parts for cleaning, and Type B which is surface cleaning without dismantling. Critical areas for cleaning facilities are also identified. CIP is described as a method for cleaning pipes and vessels internally without disassembly using circulation of cleaning solutions. A typical CIP cycle involves pre-rinse, caustic wash, intermediate rinse, acid wash, and final rinse steps. Factors like temperature, concentration, contact time and pressure/turbulence are noted to impact cleaning effectiveness.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
This document appears to be a presentation on pharmaceutical environment monitoring and microbiology. It includes a speaker profile for an expert in microbiology, information on monitoring microbes in pharmaceutical environments using Rodac plates, and acknowledges an audience at the end of the presentation. The main topics covered are pharmaceutical environment monitoring, microbiology techniques like using Rodac plates, and microbes in pharmaceutical production settings.
This document discusses environmental microbial monitoring (EMM) in cleanrooms and pharmaceutical facilities. It provides an overview of EMM purposes and regulations, who performs EMM, what areas are monitored, sampling plans and methods used. Key points covered include:
- EMM determines microbial and particulate levels to ensure cleanroom quality and identify contamination sources.
- Quality Control and Assurance departments perform EMM to demonstrate safety and ensure GMP compliance.
- Non-viable air, viable air and surface samples are monitored from areas like personnel, equipment and facilities.
- Sampling frequency, sites and methods like air samplers, settle plates, contact plates and swabbing are discussed in accordance with regulations like USP 39
This document summarizes a dissertation report submitted by Ashish Diwakar on microbial limit testing conducted at IPCA Laboratories Ltd. in Ratlam, Madhya Pradesh, India. It provides an introduction to IPCA and the principles and requirements of microbial limit testing. Methods for total bacterial count, total fungal count, and testing for pathogens like E. coli, Salmonella, P. aeruginosa, and S. aureus are described. Both direct inoculation and membrane filtration methods are covered. Requirements include various culture media, glassware, and equipment. Test procedures and observations are outlined.
The document discusses the validation of water supply systems for pharmaceutical use. It outlines the validation process, which includes design qualification to verify the system design, installation qualification to confirm proper installation, operation qualification to test system functionality under static conditions, and performance qualification to demonstrate consistent performance over time under normal operating conditions. Routine monitoring, maintenance, and change control procedures are also required to ensure continued system operation and water quality as specified.
Contamination control and sterile manufacturingGeorge Wild
Microorganisms like bacteria, viruses, and fungal spores pose a contamination risk in sterile manufacturing. Cleanrooms with strict particle and airflow controls are needed. Personnel procedures aim to minimize shedding of microbes. Sterilization methods like heat aim to achieve a sterility assurance level of 1 in 1 million by killing all microbes or reducing their number below acceptable levels. Key factors in sterilization include the bioburden level and resistance of the most durable microorganism strain present.
This document discusses cleaning validation, which provides documented evidence that approved cleaning procedures will produce equipment suitable for processing pharmaceutical products. It defines different levels of cleaning validation based on risk. Key aspects covered include cleaning techniques, establishing acceptance criteria, sampling methods, analytical methods, and documentation requirements. The goal of cleaning validation is to achieve an appropriate level of cleanliness to avoid contamination between product batches.
This document summarizes a presentation on pharmaceutical waters from the USP chapter 1231. It discusses various types of bulk and sterile waters used in pharmaceutical applications, including their sources, uses, and quality standards. Purified water and water for injection are produced in large volumes on-site for use in non-parenteral and parenteral preparations, respectively. Source water is treated and purified to meet chemical, microbial, and endotoxin limits defined in pharmacopeial monographs. Water systems must be validated to reliably produce water meeting all specified quality attributes.
The document summarizes validation of an HVAC system for a pharmaceutical facility. It discusses the importance of HVAC systems in cleanrooms and outlines some key validation parameters to test, including:
1. Airflow pattern, velocity, and changes per hour to ensure proper airflow.
2. Filter leak testing and particulate counting to check filter performance and air quality.
3. Pressure differential, temperature, humidity, and sound level testing to validate environmental controls.
Validation of the HVAC system is necessary to demonstrate that it can consistently supply air meeting quality standards to maintain aseptic manufacturing conditions.
This presentation includes detail about cleaning levels,equipments for cleaning validation , steps for cleaning method validation and analytical method validation used for cleaning.
Environmental monitoring must include surface sampling plans with sampling locations, frequency, testing times, collection methods, documentation, action levels, and responses to exceedances. Surface sampling evaluates cleaning and disinfection procedures and work practices by testing for viable microorganisms. It is an important part of maintaining a suitable microbial environment according to USP <797>, and should be performed periodically in ISO classified areas including PECs, buffer areas, and ante-areas using contact plates and swabs on flat and irregular surfaces to identify the number and types of microorganisms present.
The document provides an overview of clean rooms, including their purpose, key components, classification standards, and importance in the pharmaceutical industry. A clean room is a controlled environment designed and maintained to reduce contamination through strict control of particulate matter and other pollutants. Clean rooms are classified based on standards like ISO and use HEPA filters to purify air circulation. Proper clean room certification and validation is important for ensuring safety and quality in pharmaceutical manufacturing as required by cGMP guidelines.
Cleaning validation is an important process in the pharmaceutical industry to ensure product safety and purity. It involves documenting evidence that an approved cleaning procedure will adequately clean equipment used in pharmaceutical production. The cleaning validation process includes planning, execution, analytical testing, and reporting phases. A cross-functional team plans the validation program, which involves grouping products, equipment, cleaning agents, and methods. Sampling techniques like swab and rinse sampling are used in the execution phase. Acceptance criteria are established and analytical tests are performed on samples to verify cleaning levels. A validation report documents the results and conclusions to obtain approval. Revalidation may be required if any changes are made to the cleaning process.
This document outlines procedures for performing microbial limit tests on pharmaceutical products. The tests are designed to qualitatively or quantitatively estimate the number of viable aerobic microorganisms present or detect designated microbial species. Several methods are described, including membrane filtration, pour plate, spread plate, and multiple tube dilution. Specific procedures are provided for testing for total aerobic count, E. coli, and Salmonella. Controls and interpretation of results are also described to validate the testing methods.
The document discusses pharmaceutical water systems. It begins by defining various types of high purity water like purified water, sterile purified water, water for injection, and sterile water for injection. It then discusses how purified water and water for injection are produced, typically through processes like distillation, ion exchange, or reverse osmosis. The document also covers considerations for storing and distributing high purity water, such as using stainless steel materials, minimizing dead legs, and sanitizing distribution systems through heat, ozone, or chemicals. Finally, it presents different options for setting up hot and cold storage and distribution systems.
Good Manufacturing Practice (GMP) regulations ensure that pharmaceutical products are consistently produced and controlled according to quality standards. GMP has regulations for facilities, equipment, personnel, sanitation, testing of raw materials and finished products, manufacturing, packaging, quality control, records, and stability. Following GMP procedures guarantees high quality products for consumers by minimizing risks of contamination and ensuring correct labeling and potency. Key aspects of GMP include written procedures, process validation, environmental monitoring, and record keeping. Strict adherence to GMP is important for producing safe, effective medicines.
Good Manufacturing Practice is a set of regulations, codes, and guidelines for the manufacture of drug substances and drug products, medical devices, in vivo and in vitro diagnostic products, and foods.
Sanjeet Kumar Pandey is a B.Pharma graduate with over 10 years of experience in quality assurance and quality control roles. He is currently working as the Manager of Quality Assurance at Innova Captab Pvt Ltd in Baddi, India. He provides an overview of his work experience, education, technical skills, and personal details in his curriculum vitae.
This document provides an overview of Good Manufacturing Practices (GMP) and Pre-Requisite Programs (PRP) for maintaining food safety and quality. It discusses 10 key aspects of GMP including cleaning, pest control, personnel hygiene, and facility maintenance. It then describes 14 PRPs which expand upon GMPs and include additional programs for allergens, traceability, and cleaning validation. Finally, it provides detailed descriptions of PRP1 (cleaning and disinfection), PRP2 (pest control), and PRP3 (water quality), outlining procedures, responsibilities, and documentation required for effective implementation.
1. The document provides analysis results showing that a batch of PTAC 1881 meets specifications for appearance, content, and limits for impurities.
2. PTAC 1881 is a cationic reagent used in papermaking, textiles, and other industries to modify materials and improve properties like adhesion and water solubility.
3. The product has a transparent, colorless liquid appearance and contains over 65% active content, with impurities below detection limits. It is stored between 5-35
Danadams Pharmaceutical is a Ghanaian pharmaceutical company established in 2005 with over 250 employees. It produces antiretroviral and other pharmaceutical drugs, and was adjudged the top healthcare leader in Ghana in 2010. The company's vision is to create a healthy Africa through innovative, high quality products. This presentation discusses Danadams' manufacturing process for Danmether tablets, an antimalarial drug. The process involves raw material receipt and testing, granulation, compression, quality control testing, packaging and labeling, and storage of finished goods. Danadams is committed to complying with cGMP guidelines to ensure product quality and safety.
The document discusses Good Manufacturing Practices (GMP), which are regulations and guidelines for manufacturing drug products and medical devices to ensure quality and safety. GMP covers facility and equipment design, sanitization, personnel qualifications, documentation practices, testing of raw and finished materials, production and packaging controls, quality control, and record keeping. Following GMP is important as it aims to guarantee high quality, contamination-free products and helps prevent toxic or ineffective drugs from reaching consumers.
This document provides a summary of Surendran Sambandam's work experience and qualifications. He has over 36 years of experience in quality control, manufacturing, food safety, and regulatory affairs. He has worked in managerial roles at IFF India Ltd. and BBA (I) Ltd. overseeing quality assurance and control of flavors, fragrances, and food products. Sambandam has a B.Sc. in Chemistry and diplomas in Industrial Safety and boiler operation. He is skilled in analytical testing, auditing, process improvement, and ensuring compliance with food safety and regulatory standards.
Freshtz produces pineapple jam in Sri Lanka. They implement HACCP to improve food safety, achieve goals, reduce costs and increase consumer confidence. HACCP identifies critical control points during jam production and establishes critical limits and monitoring procedures to control biological, chemical and physical hazards. The HACCP team developed a plan outlining two critical control points - sterilization of glass bottles and pasteurization. Records of machine logs are kept to verify the HACCP plan is followed.
The document provides details about an internship completed by Aafreen Salim at the Food Analysis Laboratory of Vardan Envirolab from February 20th to May 20th, 2023. It includes an acknowledgment, introduction to the laboratory, details of the management team and various departments. Standard operating procedures for proximate analysis methods like moisture, ash, protein, fat, carbohydrate, energy and dietary fiber determination are also outlined.
In this slides you knowing about the current good manufacturing practices, there are playing crusial role in a pharmaceutical industry.
In which slides cover the cgmp objective and location of industry and follow guidelines
Good Manufacturing PracticeFor LVP,SVP, ophthalmic veterinary medicine, bulk chemicals & invitro diagnostic
For Good business Practice
A control process gives reproducibility & product consistency with in known limits
Provides license to do business.
This document provides an overview of large and small volume parenteral preparations. It begins with definitions of parenteral preparations and routes of administration. Advantages and disadvantages of the parenteral route are discussed. General requirements for parenteral dosage forms like containers, glass types, closures, and aseptic areas are covered. Parenteral preparations are classified based on volume as small volume parenterals (SVP) and large volume parenterals (LVP). Physiological considerations like pH, buffer, tonicity, and stabilizers are explained. Formulation considerations for various parenteral preparations are provided. The manufacturing process including cleaning, preparation, filtration, filling, sealing, and sterilization is outlined. Key evaluation tests like sterility testing,
Abhishek Ghara completed an industrial training at Gluconate Health Limited, a pharmaceutical manufacturing company in West Bengal.
[1] The company was formed through the merger of two companies in 1990 and is wholly owned by the government of West Bengal.
[2] Ghara thanks the managers and staff at the company for their cooperation and guidance during his training.
[3] He provides details of the company's production, quality control, packaging, and other departments as well as the instruments used and manufacturing processes for tablets, capsules, and liquids.
Luteolin is a chemical compound that is sold as a powder and used in laboratories. It is irritating to eyes, skin, and the respiratory system if inhaled. The safety data sheet provides information on safe handling, storage, exposure controls, and emergency procedures for luteolin. It also lists the product identifiers, hazards, composition, first aid measures, firefighting measures, accidental release measures, and other required safety information.
This document outlines the 12 steps of HACCP (Hazard Analysis and Critical Control Points) for canned pineapple sliced in syrup production. It includes assembling a HACCP team, describing the product, constructing a flow diagram, identifying hazards at each process step, determining critical control points, establishing monitoring and record keeping procedures, and validating that the HACCP system is working as intended. A hazard analysis is provided that analyzes biological, chemical and physical hazards for each step of canned pineapple production from receiving to distribution.
Unit 9 -Good manufacturing practice.pptxmarakiwmame
This document defines key concepts related to current good manufacturing practices (cGMP), including:
- cGMP ensures products are consistently produced and controlled to quality standards for intended use. It covers facilities, equipment, personnel, and manufacturing procedures.
- The primary goal of cGMP is to prevent errors, contamination, and mix-ups during manufacturing that could lead to unsafe or ineffective products.
- cGMP provides a framework to help ensure products are safe, effective, and high quality. It addresses premises, equipment, documentation, personnel, packaging/labeling, quality control, distribution, validation, and recall procedures.
Molecular sieve powder is essentially inert to the other formulation components. MSDS including composition ingredients, hazards information on molecular sieve powder.
ENVIRONMENT~ Renewable Energy Sources and their future prospects.tiwarimanvi3129
This presentation is for us to know that how our Environment need Attention for protection of our natural resources which are depleted day by day that's why we need to take time and shift our attention to renewable energy sources instead of non-renewable sources which are better and Eco-friendly for our environment. these renewable energy sources are so helpful for our planet and for every living organism which depends on environment.
Evolving Lifecycles with High Resolution Site Characterization (HRSC) and 3-D...Joshua Orris
The incorporation of a 3DCSM and completion of HRSC provided a tool for enhanced, data-driven, decisions to support a change in remediation closure strategies. Currently, an approved pilot study has been obtained to shut-down the remediation systems (ISCO, P&T) and conduct a hydraulic study under non-pumping conditions. A separate micro-biological bench scale treatability study was competed that yielded positive results for an emerging innovative technology. As a result, a field pilot study has commenced with results expected in nine-twelve months. With the results of the hydraulic study, field pilot studies and an updated risk assessment leading site monitoring optimization cost lifecycle savings upwards of $15MM towards an alternatively evolved best available technology remediation closure strategy.
Epcon is One of the World's leading Manufacturing Companies.EpconLP
Epcon is One of the World's leading Manufacturing Companies. With over 4000 installations worldwide, EPCON has been pioneering new techniques since 1977 that have become industry standards now. Founded in 1977, Epcon has grown from a one-man operation to a global leader in developing and manufacturing innovative air pollution control technology and industrial heating equipment.
Climate Change All over the World .pptxsairaanwer024
Climate change refers to significant and lasting changes in the average weather patterns over periods ranging from decades to millions of years. It encompasses both global warming driven by human emissions of greenhouse gases and the resulting large-scale shifts in weather patterns. While climate change is a natural phenomenon, human activities, particularly since the Industrial Revolution, have accelerated its pace and intensity
Kinetic studies on malachite green dye adsorption from aqueous solutions by A...Open Access Research Paper
Water polluted by dyestuffs compounds is a global threat to health and the environment; accordingly, we prepared a green novel sorbent chemical and Physical system from an algae, chitosan and chitosan nanoparticle and impregnated with algae with chitosan nanocomposite for the sorption of Malachite green dye from water. The algae with chitosan nanocomposite by a simple method and used as a recyclable and effective adsorbent for the removal of malachite green dye from aqueous solutions. Algae, chitosan, chitosan nanoparticle and algae with chitosan nanocomposite were characterized using different physicochemical methods. The functional groups and chemical compounds found in algae, chitosan, chitosan algae, chitosan nanoparticle, and chitosan nanoparticle with algae were identified using FTIR, SEM, and TGADTA/DTG techniques. The optimal adsorption conditions, different dosages, pH and Temperature the amount of algae with chitosan nanocomposite were determined. At optimized conditions and the batch equilibrium studies more than 99% of the dye was removed. The adsorption process data matched well kinetics showed that the reaction order for dye varied with pseudo-first order and pseudo-second order. Furthermore, the maximum adsorption capacity of the algae with chitosan nanocomposite toward malachite green dye reached as high as 15.5mg/g, respectively. Finally, multiple times reusing of algae with chitosan nanocomposite and removing dye from a real wastewater has made it a promising and attractive option for further practical applications.
Recycling and Disposal on SWM Raymond Einyu pptxRayLetai1
Increasing urbanization, rural–urban migration, rising standards of living, and rapid development associated with population growth have resulted in increased solid waste generation by industrial, domestic and other activities in Nairobi City. It has been noted in other contexts too that increasing population, changing consumption patterns, economic development, changing income, urbanization and industrialization all contribute to the increased generation of waste.
With the increasing urban population in Kenya, which is estimated to be growing at a rate higher than that of the country’s general population, waste generation and management is already a major challenge. The industrialization and urbanization process in the country, dominated by one major city – Nairobi, which has around four times the population of the next largest urban centre (Mombasa) – has witnessed an exponential increase in the generation of solid waste. It is projected that by 2030, about 50 per cent of the Kenyan population will be urban.
Aim:
A healthy, safe, secure and sustainable solid waste management system fit for a world – class city.
Improve and protect the public health of Nairobi residents and visitors.
Ecological health, diversity and productivity and maximize resource recovery through the participatory approach.
Goals:
Build awareness and capacity for source separation as essential components of sustainable waste management.
Build new environmentally sound infrastructure and systems for safe disposal of residual waste and replacing current dumpsites which should be commissioned.
Current solid waste management situation:
The status.
Solid waste generation rate is at 2240 tones / day
collection efficiently is at about 50%.
Actors i.e. city authorities, CBO’s , private firms and self-disposal
Current SWM Situation in Nairobi City:
Solid waste generation – collection – dumping
Good Practices:
• Separation – recycling – marketing.
• Open dumpsite dandora dump site through public education on source separation of waste, of which the situation can be reversed.
• Nairobi is one of the C40 cities in this respect , various actors in the solid waste management space have adopted a variety of technologies to reduce short lived climate pollutants including source separation , recycling , marketing of the recycled products.
• Through the network, it should expect to benefit from expertise of the different actors in the network in terms of applicable technologies and practices in reducing the short-lived climate pollutants.
Good practices:
Despite the dismal collection of solid waste in Nairobi city, there are practices and activities of informal actors (CBOs, CBO-SACCOs and yard shop operators) and other formal industrial actors on solid waste collection, recycling and waste reduction.
Practices and activities of these actor groups are viewed as innovations with the potential to change the way solid waste is handled.
CHALLENGES:
• Resource Allocation.
Improving the viability of probiotics by encapsulation methods for developmen...Open Access Research Paper
The popularity of functional foods among scientists and common people has been increasing day by day. Awareness and modernization make the consumer think better regarding food and nutrition. Now a day’s individual knows very well about the relation between food consumption and disease prevalence. Humans have a diversity of microbes in the gut that together form the gut microflora. Probiotics are the health-promoting live microbial cells improve host health through gut and brain connection and fighting against harmful bacteria. Bifidobacterium and Lactobacillus are the two bacterial genera which are considered to be probiotic. These good bacteria are facing challenges of viability. There are so many factors such as sensitivity to heat, pH, acidity, osmotic effect, mechanical shear, chemical components, freezing and storage time as well which affects the viability of probiotics in the dairy food matrix as well as in the gut. Multiple efforts have been done in the past and ongoing in present for these beneficial microbial population stability until their destination in the gut. One of a useful technique known as microencapsulation makes the probiotic effective in the diversified conditions and maintain these microbe’s community to the optimum level for achieving targeted benefits. Dairy products are found to be an ideal vehicle for probiotic incorporation. It has been seen that the encapsulated microbial cells show higher viability than the free cells in different processing and storage conditions as well as against bile salts in the gut. They make the food functional when incorporated, without affecting the product sensory characteristics.
Presented by The Global Peatlands Assessment: Mapping, Policy, and Action at GLF Peatlands 2024 - The Global Peatlands Assessment: Mapping, Policy, and Action
Microbial characterisation and identification, and potability of River Kuywa ...Open Access Research Paper
Water contamination is one of the major causes of water borne diseases worldwide. In Kenya, approximately 43% of people lack access to potable water due to human contamination. River Kuywa water is currently experiencing contamination due to human activities. Its water is widely used for domestic, agricultural, industrial and recreational purposes. This study aimed at characterizing bacteria and fungi in river Kuywa water. Water samples were randomly collected from four sites of the river: site A (Matisi), site B (Ngwelo), site C (Nzoia water pump) and site D (Chalicha), during the dry season (January-March 2018) and wet season (April-July 2018) and were transported to Maseno University Microbiology and plant pathology laboratory for analysis. The characterization and identification of bacteria and fungi were carried out using standard microbiological techniques. Nine bacterial genera and three fungi were identified from Kuywa river water. Clostridium spp., Staphylococcus spp., Enterobacter spp., Streptococcus spp., E. coli, Klebsiella spp., Shigella spp., Proteus spp. and Salmonella spp. Fungi were Fusarium oxysporum, Aspergillus flavus complex and Penicillium species. Wet season recorded highest bacterial and fungal counts (6.61-7.66 and 3.83-6.75cfu/ml) respectively. The results indicated that the river Kuywa water is polluted and therefore unsafe for human consumption before treatment. It is therefore recommended that the communities to ensure that they boil water especially for drinking.
Microbial characterisation and identification, and potability of River Kuywa ...
Environmental monitoring
1. ENVIRONMENNTAL
MONITORING
1. Kishan Raj Sharma
Microbiologist, QC Department
2. Prakash Ghimire
Senior Officer, QA Department
PRESENTED BY
1
Biogain Remedies Pvt. Ltd.
Patthardanda, Tilottama-16, Rupandehi, Nepal
2. INTRODUCTION
Environmental monitoring is the processes and the activities that need
to take place to characterize and monitor the quality of environment.
It is part of GMP
Monitoring
Testing
Feedback to the microbiological quality level in aseptic environment.
2
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
3. MICROBIAL MONITORING
Viable monitoring: Testing for the detection and enumeration
Bacteria, yeast and mold.
Non-viable monitoring: Particle count
3
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
4. SOURCE OF CONTAMINATION
Air
Personnel
Equipment
Cleaning agents
Containers
Water and compressed gases
4
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
5. WHERE?
Mfg Area/ dedicated location
WHEN?
The air and surface monitoring should be conducted during the
aseptic processing/operation.
Personnel monitoring when the operator leaves the process area
Product contact surface would be monitor at the end of filling
operation.
5
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
6. WHAT?
Testing /accuracy conclusion of the particular area
WHO?
The trained personnel/Microbiologist
HOW?
As per current practise
SOP/GMP/GLP/Protocols/Docs
6
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
7. METHOD FOR MICROBIAL MONITORING
Methods
Surface
monitoring
Air sampling
Contact plate
method
Swabbing
method
Touch plate
method
Surface rinse
method
Passive air
sampling
Active air
sampling
7
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
8. CONTACT PLATE METHOD
Surface sampling
Tryptone soya agar
Contact plate was pressed on the area to be tested
Wipe with 70% IPA to remove any residue
Incubate for 48 hrs at 30-35°C and then for 72 hrs at 20-
25°C
Used for testing product contact surface, floors, walls and
equipments.
8
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
9. SWABBING METHOD
Collected by removing a sterile swab from sterile
tube
Testing surface was swabbed with sterile swab
incubation
Used for testing irregular surfaces.
9
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
10. ACTIVE AIR SAMPLING
Air sampler placed in center of room at height of 1 meter
above the floor
Air sampler was disinfectant with 70% IPA
One thousand litres of air were collected
Incubate for 48 hrs at 30-35°C and then for 72 hrs at 20-25°C
Colonies were counted.
10
Reuter centrifugal
sampler
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
11. PASSIVE AIR SAMPLING
Expose petriplates containing tryptone soya agar
medium
Cover with lid
Incubate for 48 hrs at 30-35°C and then for 72 hrs at
20-25°C
11
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
12. MONITORING CRITERIA
Daily monitoring: Micro, LAF/UV passbox/ room
Monthly monitoring: MFG area/Equiments/Drain points
Quarterly monitoring: Compressed Air
Half yearly: Operators/Personal Hygiene monitoring
Yearly monitoring: HAVC (heating,ventilation and air
conditioning)
Occasional monitoring: As and when required
12
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
13. REFERENCE RANGE OF COLONY FORMING UNIT
0-5 colonies: very slight colonies(considered excellent
6-15 colonies: Slightly (considered good)
16-30 colonies: Moderate (borderline acceptable)
31-50 colonies: Significant (poor)
>50 colonies : Heavy(unacceptable)
TNTC: To numerous to count(unacceptable)
13
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
14. CONTAMINATION CONTROL
Contaminants are the presence of anything in the
manufactured product.
Contaminants can be
Product or substance other than product
manufactured
Foreign products
Particulate matter
Micro-organisms
Endotoxins
14
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
15. SOURCE OF CONTAMINATION
Personnel and their activities
Skin, hair, saliva, clothing materials,coughing,
handling,cosmectics etc
Accessories tools and equipments,glasswares
Environmental contaminants: air ,water, chemicals,
vapours, building materials etc
15
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
16. TYPES OF CONTAMINANTS
Particulate contaminants: viable and non viable particles
Physical factors: Temperature, Humidity Pressure,
Radiation, Vibration
Chemical contaminants: All other contaminants that are
not solid
16
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
17. EFFECTS
Product damage
Yield reduction
Time and economy loss
17
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
18. CONTROL
Controlling form personnel
Controlling from tools and equipment
Controlling from environment
18
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
19. CONTROL OF CONTAMINATION FROM PERSONNEL
Training
Education
Head cover, face masks and plastic boots
Disinfectant soap
Goggles
Air showers
Growing rooms
19
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
20. CONTROL OF CONTAMINANTS FROM
ACCESSORIES
HEPA
Airlock
Clean rooms
Sterilized glasswares
20
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal
21. CONTROL OF CONTAMINANTS FROM
ENVIRONMENT
Centralized air handling or fan filter units
Clean benches: horizontal and vertical laminar air flow
Careful materials and equipment selection
Gloves provide better protection from outside contamination.
21
BIOGAIN REMEDIES PVT. LTD.
Patthardanda, Tilottam-16, Rupandehi,
Nepal